AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

INDV · NASDAQ · Drug Manufacturers - Specialty & Generic

Indivior (INDV)

Develops monthly injectable and sublingual medicines for opioid use disorder.

$36.16

After hours−0.07 (−0.19%)

At close$36.23(+1.97%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	271	293	284	299	307	299	266	302	314	358	317	343
Cost of revenue	46	51	38	79	69	23	44	52	62	64	40	49
Gross profit	225	242	246	220	238	276	222	250	252	294	277	294
	408	181	171	338	234	180	156	178	153	172	140	134
Research & development	18	29	28	26	22	31	22	21	20	17	16	12
	390	157	144	152	208	−47	132	158	133	155	124	122
Selling & marketing	0	68	67	0	0	255	67	0	0	0	0	0
General & administrative	390	89	77	152	208	−302	65	158	0	0	0	0
Other expenses	0	−5	−1	160	4	196	2	−1	0	0	0	0
Operating income	−183	61	75	−118	4	96	66	72	99	122	137	160
	2	1	−2	−3	−5	−8	−7	−10	−62	−41	−22	0
Interest income	12	10	6	6	5	5	4	6	6	6	3	3
Interest expense	10	9	8	9	10	13	12	15	12	6	7	2
Other non-operating income	−12	−9	−7	−6	−5	−5	−5	−5	50	35	15	−2
Income before tax	−181	62	73	−121	−1	88	59	62	37	81	115	160
Income tax expense	−46	8	11	−23	−5	28	11	44	−5	−21	26	38
Net income from continuing operations	−135	54	62	−98	4	60	48	18	42	102	89	122
Other adjustments	0	0	−1	1	0	−1	−1	0	0	0	0	0
Net income	−135	54	61	−97	4	59	47	18	42	102	89	122
EPS, basic	−$0.94	$0.39	$0.45	−$0.72	$0.03	$0.45	$0.38	$0.14	$0.34	$0.82	$0.71	$0.97
EPS, diluted	−$0.94	$0.38	$0.45	−$0.72	$0.03	$0.45	$0.38	$0.14	$0.33	$0.82	$0.69	$0.95
Weighted average shares, basic	138	137	136	135	132	127	124	124	125	125	125	125
Weighted average shares, diluted	138	142	139	135	134	128	124	124	129	125	129	129
EBITDA	−164	79	87	−106	22	106	76	82	54	92	124	162
Depreciation & amortization	7	9	5	6	13	5	5	5	5	5	2	0
EBIT	−171	70	82	−112	9	101	71	77	49	87	122	162